Questions · Answered from the record
Thymosin Alpha-1: Common Questions
Direct answers drawn from the published literature, each cited where it makes a quantitative claim.
Does thymosin alpha 1 help with autoimmune disease?
Mechanistically it shows tolerance-promoting effects. Thymosin Alpha-1 activates dendritic-cell tryptophan catabolism through IDO — which required TLR9 and type I interferon signaling and produced IL-10 and regulatory T cells [5]. Circulating levels are also lower in psoriatic arthritis, rheumatoid arthritis, and lupus (P<0.0001) [8]. These are research findings, not evidence of treatment benefit.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (thymosin fraction 5); Goldstein and colleagues purified it and determined its complete amino-acid sequence in 1977 [1]. It is an immune-signaling peptide, cleaved in the body from the precursor prothymosin alpha.
What does thymosin alpha 1 do?
It modulates the immune system. Thymosin Alpha-1 signals through TLR2 and TLR9 on dendritic cells to drive their maturation and Th1 T-cell responses, while engaging the IDO pathway to generate regulatory T cells [5]. The result is a dual effect: restoring effector immunity in exhausted states while damping over-inflammation. It is not a muscle or growth compound.
What is thymosin alpha 1 used for?
In the research and approved-abroad record it has been used as an immune modulator — most consistently in chronic hepatitis B, and studied as an immunostimulatory adjuvant in cancers such as melanoma, hepatocellular carcinoma, and lung cancer, acting through dendritic cells and the adaptive immune response [7]. It is not approved for sale in the United States [4].
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (generic name thymalfasin) is not FDA-approved for marketing in the United States, though it is approved in roughly 35 other countries for indications such as chronic hepatitis B [4]. In the US it exists only in investigational and compounding contexts.
What is TA1 peptide?
TA1 peptide is another name for Thymosin Alpha-1 — the same 28-amino-acid, N-terminally acetylated thymic peptide that Goldstein and colleagues isolated from calf thymus and sequenced in 1977 [1]. The synthetic, sequence-identical drug form is called thymalfasin.
Who should not take thymosin alpha 1?
This site gives no human-use guidance, but the literature flags theoretical cautions: people with established autoimmune disease (it can enhance effector immunity) [8], solid-organ transplant recipients (it may counteract intentional immunosuppression) [5], and during pregnancy or lactation, where dedicated safety data are absent [4]. These are mechanistic cautions, not documented harms.
Is TB-500 the same as thymosin alpha 1?
No. TB-500 is research-material thymosin beta-4, a 43-amino-acid actin-binding peptide — a different molecule from Thymosin Alpha-1, the 28-amino-acid immunomodulator [1]. In one study the two had opposite immune effects, with alpha-1 enhancing and beta-4 suppressing lymphocyte proliferation [9]. They differ in sequence, size, mechanism, and use.
How long should you take thymosin alpha 1?
Study durations vary by setting and are not personal guidance. A comprehensive review reports multiple-dose regimens of 1.6–16 mg over five to seven days, with the standard chronic-hepatitis regimen being 1.6 mg twice weekly [4]; sepsis protocols ran five to seven days [2][3], and an NSCLC adjunct study used weekly dosing for up to 12 months.
How long does it take for thymosin alpha 1 to work?
There is no established onset timeline for individuals. Pharmacologically the peptide has a short, roughly two-hour subcutaneous half-life, returning toward baseline within about a day, so clinical regimens repeat dosing rather than rely on a single shot [4]. Immune effects are biochemical and not something a person would feel on a fixed schedule.
What is the dosing protocol for thymosin alpha 1?
Protocols differ by indication and are reported here only as research data. The comprehensive review records single doses of 0.8–6.4 mg, with 1.6 mg subcutaneous twice weekly as the standard hepatitis regimen [4]; sepsis trials used 1.6 mg every 12 hours for five to seven days [2][3]. No protocol here is a recommendation for any person.
How does thymosin alpha 1 make you feel?
Most people report feeling nothing unusual, which fits an immune modulator whose effects are biochemical rather than perceptible. In the clinical record it is generally well tolerated, with mild injection-site irritation the most common complaint [4]. Community reports of energy or resilience are subjective and labeled anecdotal on the effects page.
How much thymosin alpha 1 should I take?
This site does not provide a dose for any individual. In studies, single doses ranged from 0.8 to 6.4 mg, with 1.6 mg subcutaneous twice weekly the standard chronic-hepatitis regimen [4]. Those figures are documented trial doses in specific patient populations, not a recommendation, and US use is not approved [4].
When is the best time to take thymosin alpha 1?
The literature does not establish an optimal time of day, and this site gives no personal guidance. Clinical regimens are defined by frequency rather than time — for example 1.6 mg twice weekly in hepatitis, or every 12 hours in acute sepsis protocols — reflecting the peptide's short half-life [4][3].
Is thymosin alpha 1 safe to take?
In clinical use it has a benign documented safety profile — mild injection-site reactions are the main adverse effect, with no organ toxicity recorded at studied doses [4]. The larger safety issues are US non-approval and unregulated research-grade product quality, plus theoretical cautions in autoimmune and transplant settings [4][5]. This is not personal medical advice.
Does thymosin alpha 1 help cancer?
It has been studied as an immune adjuvant, not a standalone treatment. A reappraisal positions Thymosin Alpha-1 as an immunostimulatory adjuvant combined with chemo- and immunotherapies in melanoma, hepatocellular carcinoma, and lung cancer, potentially helping "turn a cold tumor hot" while reducing checkpoint-inhibitor toxicity [7]. These are review and combination-protocol findings, not proof of benefit.
Is thymosin alpha 1 worth it?
That is an individual judgment this site cannot make. The appraisal is that the evidence is strongest in chronic hepatitis B [14], mixed in COVID-19, and null in the largest rigorous sepsis trial (hazard ratio 0.99, P=0.93) [3]. It is also not FDA-approved in the US [4]. The record is real but uneven.
Does thymosin affect aging?
Circulating Thymosin Alpha-1 levels decline with age, and immunosenescence (age-related immune decline) is the rationale behind vaccine-adjuvant research with the peptide [4]. But no study in this record demonstrates that supplementing it slows aging; the connection is to age-related immune function, not lifespan.
Does thymosin alpha 1 reduce the mortality of severe COVID-19?
The evidence is mixed. A retrospective review of 76 patients reported significantly reduced mortality (11.11% vs 30.00%, P=0.044) with restoration of depleted T cells [6]. But a 2022 systematic review of ~5,300 patients found no statistically significant overall mortality benefit, so this should be read as suggestive, not established.
Has anyone tried thymosin alpha 1 for chronic illness or immune issues?
Within the research-use community, people dealing with post-viral fatigue or recurrent infections report subjective improvements like steadier energy and fewer colds — but these are anecdotal, not clinical evidence, and are summarized with that label on the effects page. The peptide's documented human data come from formal trials, not self-reports.
Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?
They are different molecules. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide; thymosin beta-4 ("TB-500") is a 43-amino-acid actin-binding repair peptide [1]. In the mixed lymphocyte reaction they had opposite effects — alpha-1 enhanced proliferation via helper T cells, beta-4 suppressed it via suppressor T cells [9]. Different sequence, size, mechanism, and use.
What dose of thymosin alpha 1 are people running?
This site reports only studied doses, not what individuals use. In trials, the common regimen is 1.6 mg subcutaneous twice weekly, with single doses studied across a 0.8–6.4 mg range [4]. Those are documented clinical protocols in patient populations, not a guide for personal use, and US use is not approved [4].